Extended indication

Refractory follicular lymphoma (FL)

Therapeutic value

No estimate possible yet

Registration phase

Registration application pending

Product

Active substance

Mosunetuzumab

Domain

Oncology and Hematology

Reason of inclusion

New medicine (specialité)

Main indication

Indolent non-Hodgkin’s lymphoma

Extended indication

Refractory follicular lymphoma (FL)

Manufacturer

Genentech

Route of administration

Intravenous

Therapeutical formulation

Intravenous drip

Budgetting framework

Intermural (MSZ)

Additional comments
Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulant.

Registration

Registration route

Centralised (EMA)

Type of trajectory

Accelerated assessment

Submission date

November 2021

Expected Registration

July 2022

Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet

Frequency of administration

1 times every 4 weeks

References
NCT04712097
Additional comments
Patients will receive intravenous (IV) mosunetuzumab in a step-up dosing schedule on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-12

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.